Comparative mitochondrial proteomic analysis of human large cell lung cancer cell lines with different metastasis potential

Zhenkun Liu1*, Song Xu2*, Lu Li1, Xiaorong Zhong1, Chun Chen2, Yaguang Fan2, Wang Shen2, Lingling Zu2, Feng Xue1, Min Wang2 & Qinghua Zhou1,2

1 Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, China
2 Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, China

Keywords
Cancer metastasis; lung cancer; mitochondrial protein; proteomics.

Correspondence
Qinghua Zhou, Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu 610041, Sichuan, China; Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, No. 154, Anshan Road, Heping District, Tianjin 300052, China.
Tel: + 86 28 8629 8113
Fax: +86 28 8629 8139
Email: zhouqinghua@wchscu.cn

Min Wang, Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment; Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, No. 154, Anshan Road, Heping District, Tianjin 300052, China.
Tel: + 86 22 60163013
Fax: +86 22 60363012
Email: wangmin@tjmu.edu.cn

*These authors contributed equally to this work.

Received: 25 February 2019;
Accepted: 3 March 2019.
doi: 10.1111/1759-7714.13052
Thoracic Cancer 10 (2019) 1111–1128

Abstract
Background: Lung cancer is a highly aggressive cancer with a poor prognosis and is associated with distant metastasis; however, there are no clinically recognized biomarkers for the early diagnosis and prediction of lung cancer metastasis. We sought to identify the differential mitochondrial protein profiles and understand the molecular mechanisms governing lung cancer metastasis.

Methods: Mitochondrial proteomic analysis was performed to screen and identify the differential mitochondrial protein profiles between human large cell lung cancer cell lines with high (L-9981) and low (NL-9980) metastatic potential by two-dimensional differential gel electrophoresis. Western blot was used to validate the differential mitochondrial proteins from the two cells. Bioinformatic proteome analysis was performed using the Mascot search engine and messenger RNA expression of the 37 genes of the differential mitochondrial proteins were detected by real-time PCR.

Results: Two hundred and seventeen mitochondrial proteins were differentially expressed between L-9981 and NL-9980 cells (P < 0.05). Sixty-four analyzed proteins were identified by matrix-assisted laser desorption/ionization-time of flight mass spectrometry coupled with database interrogation. Ontology analysis revealed that these proteins were mainly involved in the regulation of translation, amino acid metabolism, tricarboxylic acid cycle, cancer invasion and metastasis, oxidative phosphorylation, intracellular signaling pathway, cell cycle, and apoptosis.

Conclusion: Our results suggest that the incorporation of more samples and new datasets will permit the definition of a collection of proteins as potential biomarkers for the prediction and diagnosis of lung cancer metastasis.

Introduction
Lung cancer is the leading cause of cancer-related death of both men and women worldwide.1–9 Poor survival is associated with tumor metastasis.10–15 Lung cancer metastasis is not only the malignant marker but is the main cause of treatment failure.16–20 Metastasis is a complex
biological behavior that is correlated with many factors, genes, signal pathways, and biological processes. Therefore, exploration of changes to molecular genetics and cell signal transduction related to invasion and metastasis in lung cancer will not only illuminate the molecular mechanisms of tumor invasion and metastasis, but also provide a new targeting molecule and route for blocking signal transduction and reversing the metastatic phenotype of lung cancer. Our previous studies showed that low expression and hetero-deletion of tumor metastasis suppressor gene nm23-H1 are closely correlated with high metastatic ability and poor prognosis in lung cancer patients. We also demonstrated that transfection of wild type nm23-H1 complementary DNA (cDNA) into human high-metastatic large cell lung cancer cells (which exhibit loss of heterozygosity [LOH] of nm23-H1), can regulate the expression of metastatic relative genes and reverse the metastatic phenotype of lung cancer cell lines. Our findings and other reports have provided sufficient evidence to indicate that nm23-H1 is a metastasis suppressor gene in many tumors. Our studies have also proven that the nm23-H1 gene is a key and upstream regulative gene in the “lung cancer metastatic suppressive cascade.” However, the exact molecular mechanism by which nm23-H1 suppresses or reverses lung cancer metastasis is unclear.

Mitochondria are important organelles in cellular physiology. They have their own genomic system independent from the nucleus, and possess their own transcription, translation, and protein assembly machinery. They are the principal suppliers of adenosine triphosphate, playing a central role in cellular energy metabolism and apoptosis. The oxidative metabolism of mitochondria contributes to harmful protein modifications, even under normal conditions. Mitochondrial function changes have been implicated in tumor formation, including increased production of reactive oxygen species (ROS), decreased oxidative phosphorylation, and a corresponding increase in glycolysis. Recently, deregulated cellular energetics have been considered an additional emerging hallmark of cancer. Cancer cell signaling regulated by kinases and phosphatases is guided by cellular redox status and may be key in malignant transformation.

The protection of mitochondrial protein function is an important aspect of cellular protein quality control. However, mitochondrial proteins are difficult to characterize because of their relatively low abundance. Subcellular proteomic research would represent a significant advance in the profiling of mitochondrial changes in diseased cells. Two-dimensional differential in gel electrophoresis (2D-DIGE), coupled with matrix assisted laser desorption-ionization-time of flight (MALDI-TOF) mass spectrometry (MS) has is frequently been applied in this field. However, mitochondrial proteomic profiles in non-small cell lung cancer (NSCLC) remain poorly defined, particularly related to lung cancer metastasis. We conducted differential profiling of mitochondrial proteins from NSCLC cell lines with high and low metastatic potential and analyzed mitochondria-related metabolic pathways to identify the possible molecular markers of NSCLC metastasis.

**Methods**

**Cell lines and reagents**

A human high metastatic large cell lung cancer cell line (L9981) and low metastatic large cell lung cancer cell line (NL9980) were established from a human lung large cell carcinoma cell line (WCQH-9801) in our laboratory. Cell lines were cultured in RPMI 1640 medium containing 10% fetal bovine serum (Gibco, Grand Island, NY, USA) at 37°C with 5% CO2 incubator. Cy2, Cy3, and Cy5 were purchased from GE Healthcare (Piscataway, NJ, USA). Immobiline pH-gradient (IPG) DryStrips (pH 3–10,24 cm), IPG buffer (pH 3–10), DryStrip cover fluid, thiourea, urea, dithiothreitol (DTT) , Pharmalyte (pH 3-10), bromophenol blue, Commassie Brilliant Blue G-250, Tris base, sodium dodecyl sulfate (SDS), and molecular weight marker were purchased from Amerham Biosciences (Uppsala, Sweden).

Modified trypsin (sequencing grade) was obtained from Promega (Madison, IL, USA). Sucrose and mannitol were purchased from Sango (Shanghai, China). All analytical grade chemicals and biochemicals were prepared with Milli-Q deionized water (Millipore, Bedford, MA, USA).

Primary anti-fumarate hydratase (sc-27995), PRDX3 (sc-23969), HSP75 (TR1) (sc-13557), ERAB (sc-58525), PCNA (sc-56), and cytochrome c (SC-13560) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), and anti-PHB (sc2426) and COX IV (#4844) antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA).

**Isolation and purification of mitochondria**

Cells were collected by centrifugation at 700 g for 10 minutes and the pellets were resuspended in homogenization medium A (20 mM Hepes-KOH, 1 mM ethylene-diaminetetraacetic acid [EDTA], 1 mM phenylmethylsulfonyl fluoride [PMSF], 50 mM sucrose, 200 mM mannitol, pH7.4). The suspension was left on ice for 10 minutes. Cells were then dounce-homogenized and the lysis was monitored for quality by using phase-contrast microscopy until at least

---

**Lung cancer metastasis mitochondrial proteomic**

Z. Liu et al.
90% of the cells were broken. The homogenate was centrifuged at 1000g for 10 minutes at 4°C and supernatant A was collected. The pellets were then washed twice with homogenization Medium B (20 mM Heps-KOH, 25 mM KCl, 5 mM MgCl2, 1 mM PMSF, 250 mM sucrose, pH7.4), and saved as the nuclear fraction. Supernatant A was centrifuged at 12,500g for 15 minutes at 4°C, and the pellet was collected and then washed once as a heavy membrane pellet. The heavy membrane pellet was resuspended in homogenization Medium A and spun again at 4000 g for 15 minutes to obtain the heavy mitochondrial pellet.

The heavy mitochondrial pellet was overlaid on a sucrose step density gradient (1.0 M sucrose over 1.5 M sucrose in 10 mM Tris_HCl [pH 7.4], 1 mM EDTA). The preparation was ultracentrifuged at 60 000 g for 20 minutes at 4°C to obtain mitochondria-enriched pellets. The pellets were washed twice in homogenization medium A.

**Sodium dodecyl sulfate-polyacrylamide gel electrophoresis**

The mitochondria-enriched pellets were suspended in the loading buffer (50 mM Tris-HCl, pH 6.8, 100 mM DTT, 2% SDS, 0.1% bromophenol blue, 10% glycerol) and run on SDS-polyacrylamide gel electrophoresis (PAGE, T = 12%) in Tris-glycine running buffer with 50 μg of protein per lane.

**Western blot analysis**

The mitochondria proteins were transferred to nitrocellulose membrane (Amersham Biosciences) under wet conditions at 80 V for two hours. Blots were blocked with blocking buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% Tween-20, 5% nonfat dried milk) for one hour at room temperature. Different organelle marker protein antibodies and other primary antibodies were then added and the proteins were incubated overnight at 4°C. The blot was washed with TBST (20 mM Tris-HCl, 150 mM NaCl, 0.05% Tween-20, pH 7.5). The films were scanned using the Powerlook scanner (UMAX Technologies, Dallas, TX, USA) and quantified by Image Quant software (TL 7.0).

**Two-dimensional differential in gel electrophoresis of mitochondria proteins**

The mitochondria-enriched pellets were dissolved in lysis buffer (7 M urea, 2 M thiourea, 4% 3-(3-cholamidopropyl)dimethylammonio)-1-propanesulfonate [CHAPS], 30 mM Tris, 1 mM PMSF, pH8.5) at 4°C for one hour with intermittent sonication and then centrifuged at 20 000g for 30 minutes at 4°C. Protein extracts were purified using the Ettan 2D CleanUp kit (Amersham Biosciences) according to manufacturer’s instructions, and adjusted to pH 8.5. The concentration of the total proteins was measured by using a 2D Quant kit (Amersham Biosciences).

The mitochondria protein lysates from two cell lines were labeled with Cy2, Cy3, and Cy5 following the protocols described in the Ettan DIGE User Manual (18-1164-40 Edition AA, GE Healthcare). Typically, 50 μg lysates were labeled with 400 pmol of Cy3 or Cy5, while the same amount of the pool standard of both samples was labeled with Cy2. We crossed fluorochromes between the pairs of analyzed samples to avoid differences resulting from the staining effectiveness. To achieve statistical confidence, three biological replicates were employed. Labeling reactions were carried out in the dark on ice for 30 minutes before quenching with 1 μL of 10 mM lysine for 10 minutes on ice. These labeled samples were then combined for 2D-DIGE analysis.

Cy3 and Cy5 labeled samples (50 μg) were combined before mixing with 50 μg Cy2 labeled internal standards. An equal volume of 2× sample buffer (7 M urea, 2 M thiourea, 4% CHAPS, 30 mM Tris, 1 mM PMSF, 130 mM DTT, 2% IPG buffer) was added to the sample and the total volume was made up to 450 μL with rehydration buffer (7 M urea, 2 M thiourea, 2% CHAPS, 15 mM DTT, 0.5% IPG buffer). The proteins were applied to IPG strips (pH 3-10, linear, 24 cm) and focused on an IPGphorIII (Amersham Biosciences) for a total of 64 kVh. The focused IPG strips were equilibrated and then applied to 12.5% SDS-PAGE using low-fluorescence glass plates on an Ettan DALT SIX system (Amersham Biosciences). All electrophoresis procedures were performed in the dark. After SDS-PAGE, the gels were scanned on a Typhoon 9400 scanner (GE Healthcare) at appropriate excitation/emission wavelengths specific for Cy2 (488/520 nm), Cy3 (532/580 nm), and Cy5 (633/670 nm) to generate spot maps. We prepared another strip in parallel as a preparative gel for spot pickings using the same process, except the IPG strip was loaded with 1000 μg proteins and the gel was stained with Coomassie brilliant blue.

**Imaging analysis**

DeCyder 6.5 software was used for 2D-DIGE analysis, according to the manufacturer’s recommendations. The DeCyder differential in-gel analysis (DIA) module was used to compare each cell line mitochondria protein sample to the internal standard in each gel. The DeCyder biological variation analysis module was then used to simultaneously match all spot maps, using Cy3: Cy2 and Cy5: Cy2 DIA ratios, to calculate average abundance.
changes and Student’s t-test P values for the variance of these ratios for each protein across all samples. The differential protein spots (|ratio| NL9980/L9981 ≥ 1.2, P ≤ 0.05) were selected for identification.

### Protein identification by mass spectrometry (MS)

Spots of interest were chosen using an Ettan Spot Picker from the preparative gel, destained, and digested with in-gel trypsin. Tryptic peptides (0.5 μL) were mixed with 0.5 μL matrix solution (α-cyano-4-hydroxycinnamic acid [CHCA] in 50% acetonitrile [ACN]/0.1% trifluoroacetic acid [TFA]) and then analyzed using an AutoFlex MALDI-TOF/TOF mass spectrometer with LIFT technology (Bruker Daltonics, Bremen, Germany) to obtain the peptide mass fingerprint. Peptide matching and protein searches against the NCBI-nr database were performed using the Mascot search engine (http://www.matrixscience.com/) with a mass tolerance of ±100 ppm.

### Functional enrichment analyses of mitochondrial differential proteins and protein–protein interaction data

The gene names of mitochondrial differential expression proteins were converted to NCBI-Entrez format for consistency and saved as a text file that was input into Cytoscape version 3.0.2 (www.cytoscape.org), BiNGO plugin 3.0.2, and AgilentLiteratureSearch 3.0.3.beta downloaded from Cytoscape manage plugin was used to analyze the enriched biological processes, molecular functions, and literature based protein–protein interaction network studies.

### RNA isolation, reverse transcription reaction, and real-time PCR

Total cellular RNA was isolated from 5 × 10^6 cells using the Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions, and quantified using an ultraviolet spectrophotometer (Beckman Coulter, Fullerton, CA, USA).

RNA (2 μg) was reverse transcribed using an M-MLV Reverse Transcriptase Kit (Promega) according to the manufacturer’s protocol. Resultant cDNA (20 ng) was mixed with SYBR Green Master Mix (Applied Biosystems by Life Technologies, Foster City, CA, USA) and interest genes primer and amplified in the ABI7500 Real-time PCR System according to the manufacturer’s protocol. The results of relative quantification were analyzed by comparison of $2^{ΔΔC_{T}} × 100\%$. The PCR primers are shown in Table 1.

### Statistical analysis

Data are presented as means ± standard deviation and the t-test was used to analyze the differences between NL9980 and L9981 cell lines. $P < 0.05$ was considered statistically significant. PCR and Western Blot analyses were repeated at least three times.

### Results

#### Enrichment of mitochondrial fractions

After protein extraction, we performed Western Blot analysis using cytochrome c, a mitochondrial marker, and PCNA, a nuclear marker. Cytochrome c was enriched while PCNA was barely detectable in the mitochondrial fraction, indicating that mitochondrial enrichment was not contaminated by proteins from other subcellular compartments (Fig 1).

#### Identification of differential proteins by MS

The mitochondria proteins of NL9980 and L9981 cell lines were compared by DIGE analysis and the mean number of spots detected in the three gels was 2333 ± 96.2 (Fig 2). Among 1722 ± 311.1 matched protein spots, 217 spots were differentially expressed in NL9980 and L9981 cell lines (|ratio| NL9980/L9981 ≥ 1.2). Sixty-four protein spots with the most remarkable alteration were further analyzed by MALDI-TOF peptide fingerprint and their molecular functions were summarized (Table 2).

#### Functional enrichment analyses of mitochondrial differential proteins and protein–protein interaction data

Functional enrichment category analyses of mitochondrial differential proteins were identified. The functional enrichment maps of the biological process and molecular function are shown in Figures 3 and 4, respectively. The white color shows non-significance in enrichment analysis; the color range from yellow to orange shows an adjusted P value from 0.05 to < 5*10^-7. The statistical significantly enriched biological processes and molecular functions (P < 0.05, adjusted using the Bonferroni correction) are listed in Table 3. Biological processes, such as cellular respiration, energy derivation by oxidation of organic compounds, electron transport chain, respiratory electron transport chain, cellular metabolic process, generation of precursor metabolites and energy, oxidation reduction, and the metabolic process were enriched. Molecular functions,
such as oxidoreductase and catalytic activity, were also enriched. The results showed that most of enriched proteins of the identified mitochondrial differential proteins were oxidoreduction-related proteins and biological processes were oxidoreduction-related processes.

A literature based protein–protein interaction subnetwork of mitochondrial differential proteins was generated using AgilentLiteratureSearch from CytoScape. The results are shown in Figure 5. In this subnetwork, the colored circles (nodes) represent proteins, the yellow circles represent the proteins from our results, and the grey full lines (edges) represent protein–protein interactions. Mitochondrial differential proteins, such as PRDX3, SOD2, PHB, HSP75 (TRAP1) and GLS, more frequently interacted with other proteins. These interaction data provide important insight into the molecular mechanisms of NSCLC metastasis.

### Validation of differentially expressed proteins on gene level by real-time PCR

To verify the 2D-DIGE profiling results, we selected 37 genes and detected their expression by real time PCR. The genetic alterations of selected mitochondria proteins conformed to the 2D-DIGE data (Fig 6).
Validation of differentially expressed proteins by Western blotting

To further validate the 2D-DIGE profiling result from protein level, we performed Western blot analysis on several interesting mitochondrial proteins, including FH, PRDX3, HSP75, ERAB, and PHB. The expression of recruited proteins was significantly higher in NL9980 cells compared to L9981 cells, which was consistent with results from the 2D-DIGE data (Fig 7).

Discussion

To a large extent, the poor prognosis of lung cancer is associated with its malignant metastatic phenotype. To better explore and understand the mechanism of lung cancer metastasis and to search for potential markers for early diagnosis and reverse metastasis, we previously performed differential proteomic analysis in two human large cell lung cancer cell lines with high (L9981) and low (NL9980) metastasis potential by 2D-DIGE. The data suggest that obvious differential proteomic expression exists between human high and low metastatic large cell lung cancer cell lines. Although the molecular mechanisms have gradually been deciphered, the function of mitochondria in the process of lung cancer metastasis remains unknown. Some studies have demonstrated that in certain tumors, such as nasopharyngeal and hepatocellular carcinoma, mitochondrial proteins are the potential biomarkers for cancer initiation and progression. Therefore, we proposed that mitochondrial proteins might be differentially expressed in lung cancer metastasis.
| Master No. | Accession No. | t-test | Av. Ratio | Protein name | Reported molecular function | Calculated PI value | Nominal mass (Mr) | Sequence covered (%) | Score |
|-----------|---------------|--------|------------|--------------|------------------------------|---------------------|-------------------|---------------------|-------|
| 625       | gi|5822580   | 0.00074   | -10.41      | Chain A, crystal structure of the human Pax-6 Paired domain-DNA complex reveals a general model for Pax protein-DNA interactions | 9.86               | 14 744            | 45                  | 66                |
| 1405      | gi|186669512  | 0.00016   | -8.63       | CAMSAP1                                                                | 6.28               | 179 230           | 6                   | 67                |
| 1423      | gi|83405782   | 0.000085  | -7.35       | VEPH1                                                                  | 6.28               | 90 436            | 9                   | 66                |
| 1339      | gi|4324699    | 0.00019   | -7.25       | NUMA1                                                                  | 10.56              | 31 952            | 37                  | 68                |
| 1324      | gi|4457970    | 0.00085   | -7.01       | CAMSAP1 Homo sapiens cDNA clone IMAGE:2176589 Homo sapiens cDNA clone IMAGE:2176589 mRNA sequence | 9.46               | 10 934            | 60                  | 92                |
| 1490      | gi|77939099   | 0.0012    | -6.53       | MCF7RNAL18G24TF Homo sapiens cDNA clone MCF7_RNA_L_18_G24 mRNA sequence | 5.44               | 19 514            | 34                  | 92                |
| 1424      | gi|56666319   | 0.00024   | -6.41       | CASK (MAGUK family)                                                    | 5.83               | 67 245            | 18                  | 74                |
| 1831      | gi|5454090    | 0.0038    | -6.37       | SSR4                                                                  | 5.76               | 19 158            | 35                  | 111               |
| 1170      | gi|77935996   | 0.00097   | -6.32       | MCF7RNAL16B02TR Homo sapiens cDNA clone MCF7_RNA_L_16_B02, mRNA sequence | 6.17               | 23 959            | 42                  | 122               |
| 1036      | gi|76827262   | 0.00097   | -6.1        | ETV2                                                                  | 9.16               | 17 837            | 30                  | 67                |
| 1420      | gi|34536332   | 0.00097   | -5.54       | GFAP                                                                  | 5.84               | 49 533            | 12                  | 54                |
| 1420      | gi|34782991   | 0.00097   | -5.54       | INPP5B                                                                 | 5.44               | 85 202            | 8                   | 54                |
| 1451      | gi|74733472   | 0.00099   | -4.16       | MRPL1                                                                  | 8.19               | 34 602            | 27                  | 78                |
| 1629      | gi|49119653   | 0.00049   | -1.67       | YWHAZ                                                                  | 4.72               | 30 100            | 38                  | 100               |
| 1343      | gi|13786630   | 0.017     | -1.58       | Chain A, crystallographic structure of human branched chain amino acid aminotransferase (mitochondrial) complexed with PLP at 1.95 angstroms (orthorhombic form) | 8.48               | 41 635            | 29                  | 94                |
| 685       | gi|18677024   | 0.01      | -1.24       | PDE2                                                                  | 6.33               | 59 567            | 31                  | 87                |
| 685       | gi|50513540   | 0.01      | -1.24       | Chain A, Moesin FERM domain bound to EBP50 C-terminal peptide          | 9.03               | 35 010            | 32                  | 75                |
| 917       | gi|6002671    | 0.00084   | 3.82        | GAC                                                                   | 6.05               | 58 678            | 17                  | 98                |
| 1431      | gi|j1361454   | 0.00032   | 3.25        | PYCR2                                                                  | 7.66               | 33 958            | 35                  | 116               |
| Master No. | Accession No. | t-test | Av. Ratio | Protein name | Reported molecular function | Calculated PI value | Nominal mass (Mr) | Sequence covered (%) | Score |
|-----------|---------------|--------|-----------|--------------|-----------------------------|--------------------|------------------|-----------------------|-------|
| 670       | gi|14149738    | 0.0032  | 2.8         | Neurolysin | Proteolysis                  | 6.21               | 81 341           | 40                    | 200   |
| 1526      | gi|110349780   | 0.0012  | 2.58        | ATPAF1 isofrom 1 precursor | Malate metabolic process, metabolic process | 7.53               | 66 029           | 37                    | 166   |
| 799       | gi|4505145     | 0.0033  | 2.54        | MEZ, NAD(+)-dependent, mitochondrial | Translation, RNA binding, structural constituent of ribosome | 8.19               | 34 602           | 33                    | 84    |
| 1434      | gi|7473472     | 0.0026  | 2.45        | MRPL1      | Epithelial cell differentiation, actin filament binding | 5.94               | 69 313           | 28                    | 154   |
| 580       | gi|46249758    | 0.0026  | 2.39        | Ezrin      | ATPAF1 isoform 1 precursor  | 8.12               | 36 756           | 33                    | 180   |
| 1685      | gi|119612044   | 0.0045  | 2.39        | FAM82B, isofrom CRA_a | Acetyl-CoA metabolic process, glycolysis, metabolic process | 8.35               | 43 934           | 40                    | 130   |
| 1088      | gi|62897039    | 0.0085  | 2.36        | PDC (lipoamide) alpha 1 variant | Cell proliferation, mitochondria translation | 6.14               | 37 775           | 26                    | 54    |
| 1172      | gi|4557231     | 0.0088  | 2.19        | ACAD C-4 to C-12 straight chain isofrom, a precursor | Electron transport, lipid metabolic process | 8.61               | 47 015           | 44                    | 198   |
| 1594      | gi|40226380    | 0.0024  | 2.19        | ABHD11     | Proteolysis, aromatic compound metabolic process | 9.24               | 34 310           | 28                    | 115   |
| 1678      | gi|83715985    | 0.00097 | 2.12        | HSD17B10 isofoam 2 | Lipid metabolic, metabolic, enterobactin biosynthetic, and cellular metabolic processes | 6.73               | 26 196           | 67                    | 142   |
| 1095      | gi|46593007    | 0.0029  | 2.09        | UQCRC1     | Electron transport, oxidative phosphorylation, proteolysis, transport, aerobic respiration | 5.94               | 53 297           | 35                    | 118   |
| 923       | gi|62088986    | 0.001  | 2.04        | DLD, variant | Electron transport, transfer RNA processing, cell redox homeostasis | 8.71               | 56 129           | 22                    | 99    |
| 1356      | gi|33337737    | 0.0024  | 2.04        | SAMM50     | Biological process | 6.44               | 52 271           | 39                    | 133   |
| 709       | gi|119631857   | 0.0085  | 1.91        | MRPL39     | Ubiquinone biosynthetic process, metabolic process | 6.47               | 37 402           | 45                    | 152   |
| 1606      | gi|7524346     | 0.001  | 1.89        | AK2 isoform b | Protein targeting | 8.32               | 80 228           | 27                    | 123   |
| 740       | gi|156105687   | 0.0012  | 1.88        | MIP        | TRAP1 variant | 8.00               | 38 695           | 32                    | 138   |
| 1664      | gi|119573328   | 0.0017  | 1.88        | APOA1 isoform CRA_c | Glucose catabolic process, glycerol-3-phosphate metabolic process, gluconogenesis, electron transport, insulinoma, non-insulin-dependent diabetes mellitus | 7.23               | 79 202           | 23                    | 97    |

Lung cancer metastasis mitochondrial proteomic Z. Liu et al.
| Master No. | Accession No. | t-test | Av. Ratio | Protein name | Reported molecular function                                                                 | Calculated PI value | Nominal mass (Mr) | Sequence covered (%) | Score |
|-----------|---------------|--------|-----------|--------------|---------------------------------------------------------------------------------------------|---------------------|-------------------|---------------------|-------|
| 1302      | gi|46593007     | 0.0013 | 1.86       | UQCRC1       | Electron transport, oxidative phosphorylation, proteolysis, transport, aerobic respiration    | 5.94               | 53 297            | 42                  | 166   |
| 1916      | gi|4826848      | 0.00018| 1.86       | NDUFA5       | Electron transport, mitochondrial electron transport, NADH to ubiquinone                   | 5.75               | 13 507            | 42                  | 124   |
| 1660      | gi|45768728     | 0.000097| 1.85       | UQCRFS1      | Electron transport, transport                                                              | 8.55               | 29 958            | 29                  | 112   |
| 1169      | gi|15342081     | 0.00032| 1.84       | MRPL38       | Cell motility                                                                               | 6.2                | 41 017            | 52                  | 200   |
| 572       | gi|4505257      | 0.00037| 1.79       | Moesin       | Lipid metabolism                                                                            | 6.32               | 27 250            | 32                  | 114   |
| 1589      | gi|16307101     | 0.0025 | 1.69       | DCI          | Protein amino acid dephosphorylation, mitochondrial membrane organization and biogenesis,    | 8.56               | 39 014            | 38                  | 190   |
| 1301      | gi|14290586     | 0.00024| 1.69       | TIMM50       | Protein transport across a membrane                                                         | 8.85               | 54 773            | 33                  | 158   |
| 1093      | gi|19743875     | 0.0055 | 1.66       | FH precursor | Tricarboxylic acid cycle, fumarate metabolic process, cell cycle, negative regulation of     | 6.49               | 45 758            | 18                  | 82    |
| 1139      | gi|4758786      | 0.00065| 1.66       | NDUFS2       | Electron transport, mitochondrial electron transport, NADH to ubiquinone, response to       | 7.21               | 52 911            | 27                  | 105   |
| 1138      | gi|48257138     | 0.00091| 1.65       | Citrate synthase | Carbohydrate metabolic process, tricarboxylic acid cycle                                 |                   |                   |                     |       |
| 1665      | gi|51389999     | 0.0015 | 1.65       | NADH-Ubiquinone reductase                                                                  | 7.77               | 30 401            | 51                  | 252   |
| 1932      | gi|18644883     | 0.0036 | 1.65       | ATP5F,         | Generation of precursor metabolites and energy, ion transport, ATP synthesis-coupled          | 9.52               | 12 580            | 54                  | 94    |
| 1553      | gi|4505773      | 0.0011 | 1.64       | PHB          | Regulation of progression through cell cycle, DNA replication, signal transduction, negative | 5.57               | 29 843            | 41                  | 162   |
| Master No. | Accession No. | t-test | Av. Ratio | Protein name | Reported molecular function | Calculated PI value | Nominal mass (Mr) | Sequence covered (%) | Score |
|-----------|---------------|--------|-----------|--------------|-----------------------------|--------------------|------------------|---------------------|-------|
| 1586      | gi|4502013  | 0.000097 | 1.64        | AK2 isoform A               | Nucleoside, nucleotide, and nucleic acid metabolic process | 7.67              | 26 689              | 35                 | 104          |
| 1142      | gi|704416   | 0.0081  | 1.62        | EF-Tu                      | DNA/RNA/protein synthesis | 7.7               | 49 851              | 3                  | 37            |
| 971       | gi|116241244 | 0.0007  | 1.61        | ALDH7A1                    | Aldehyde dehydrogenase (NAD) activity, L-aminoacidipate-semialdehyde dehydrogenase activity, oxidoreductase activity | 6.44              | 55 845              | 25                 | 73            |
| 1227      | gi|21914862 | 0.00038 | 1.54        | CECR5                      | Activation of NF-kappaB transcription factor | 3.33333E+13       | 6.43               | 43 845             | 41            |
| 1217      | gi|119569781 | 0.00043 | 1.53        | PRDX3, isoform CRA_a       | Activation of NF-kappaB transcription factor | 3.33333E+13       | 6.43               | 43 845             | 41            |
| 1296      | gi|433888   | 0.0026  | 1.48        | CPOX                       | Porphyrin and chlorophyll metabolism | 6.68              | 40 847              | 53                 | 238           |
| 986       | gi|122065129 | 0.0057  | 1.4         | ALDH3B1 (ALDH class 2)     | Glycolysis/gluconeogenesis | 6.36              | 57 658              | 24                 | 133           |
| 962       | gi|7588925  | 0.00079 | 1.39        | LAP3                       | Glycolysis/gluconeogenesis | 3.33333E+13       | 6.80               | 54 754             | 49            |
| 973       | gi|119577249 | 0.019   | 1.31        | SARS2, isoform CRA_b       | Superoxide dismutase activity, manganese superoxide dismutase activity, oxidoreductase activity, manganese ion binding, metal ion binding | 6.79              | 53 699              | 15                 | 66            |
| 1756      | gi|38503339 | 0.0018  | 1.26        | SOD [Mn], mitochondrial    | Superoxide dismutase activity, manganese superoxide dismutase activity, oxidoreductase activity, manganese ion binding, metal ion binding | 6.86              | 22 304              | 43                 | 93            |

T-test and Av. Ratio: NL9980/L9981.
Routine protein analysis to detect mitochondrial proteins is difficult because of their low expression compared to non-mitochondrial proteins. In this study, we conducted 2D-DIGE analysis combined with MALDI-TOF/TOF to evaluate the differences in mitochondrial protein expression between two human large cell lung cancer cell lines with high (L9981) and low (NL9980) metastatic potential. Two dimensional-DIGE revealed 217 differential spots between the two cell lines, while MS revealed a further 64 spots with significant differences. Interestingly, a number of non-mitochondrial proteins that presented in the enriched mitochondria fraction were also differentially expressed between the two cell lines. These proteins are either peripherally associated with the mitochondria, sublocated in the mitochondria, or present as possible contaminants in the preparation. Nevertheless, according to Swiss-Prot annotation, the majority of the differentially expressed proteins were localized in the mitochondria. Among these candidates, six proteins piqued our interest, including FH, HSP75, ERAB, PHB, and PRDX3, which have previously been reported to be involved in cancer development and metastasis.

Loss-of-function of FH, a metabolic tumor suppressor, is associated with hereditary leiomyomatosis and renal cell carcinoma. Studies have shown that FH-deficient cancer is characterized by impaired oxidative phosphorylation and a metabolic shift to aerobic glycolysis, a form of metabolic reprogramming referred to as the Warburg effect. These changes represent multiple biochemical adaptations in the glucose and fatty acid metabolism that supports malignant proliferation. To date, no reports have identified the relevance of FH in lung cancer development and metastasis; however, in our study, we observed that L9981 cells showed significantly low expression of FH compared to NL9980 cells. As FH is reported to be a metabolic tumor suppressor, we assumed that FH might negatively regulate lung cancer invasion and metastasis.

HSP75, also called tumor necrosis factor type I receptor-associated protein (TRAP-1), is another downregulated mitochondrial protein with high metastatic ability in L9981 cells. HSP75 is a negative regulator of mitochondrial respiration that can modulate the balance between oxidative phosphorylation and aerobic glycolysis. The impact of HSP75 on mitochondrial respiration...
is probably mediated by the modulation of mitochondrial spare respiratory capacity (SRC) and the inhibition of SDHA. Previous studies have indicated that HSP75 expression is significantly reduced in bladder cancer and renal cell carcinoma compared to healthy tissues, but is increased in other types of tumors. \cite{52-54} Recently, Agorreta et al. reported that HSP75 impacts the viability of NSCLC cells, and that its expression is prognostic in NSCLC. \cite{55} Liu et al. confirmed that HSP75 could stimulate the proliferation of lung cancer cells but inhibits metastatic spread. \cite{56} However, Caino et al. reported contradictory findings, reporting that HSP75 favors metastatic dissemination in disease models in mice, and shortens overall survival in patients with NSCLC, \cite{57} indicating that the role of HSP75 is complex in lung cancer metastasis.

Figure 4 Enriched molecular functions of differentially expressed mitochondrial proteins between NL9980 and L9981 cell lines with low and high metastatic potential. Color circles represent molecular functions, arrows represent the relationship between two molecular functions, white circles show non-significance in enrichment analysis, and the color range from yellow to orange shows adjusted \( P \) values from 0.05 to < 5*10^-7.
ERAB is characterized as a NAD+-dependent dehydrogenase that is constitutively expressed in tissues and overexpressed in neurons affected in Alzheimer’s disease. Cells overexpressing ERAB in vitro are more sensitive to β-Amyloid-induced stress, and blocking ERAB activity has been shown to inhibit this cell death, indicating that β-Amyloid induced cell death is mediated by ERAB.\textsuperscript{58,59} The role of ERAB in tumors has rarely been reported. The only study we located by Shen et al. indicated that ERAB is differentially expressed in HOXA13 knockdown esophageal squamous cell carcinoma cells.\textsuperscript{60}

PHB is an evolutionary conserved protein that responds to mitochondrial stress and plays a role in regulating mitochondrial respiration activity.\textsuperscript{61} It is considered a regulator of cell growth, proliferation, differentiation, aging, and apoptosis.\textsuperscript{62} The role of PHB in cancer cell growth remains controversial. Many reports have shown evidence that PHB overexpression results in the inhibition of cancer cell growth, but the knockdown of PHB by small interfering RNA (siRNA) accelerates tumor growth in prostate, gastric, and liver cancers.\textsuperscript{63-65} However, other studies have suggested that PHB plays a protumorigenic role. PHB is necessary for the activation of C-Raf by the oncogene Ras in HeLa cells.\textsuperscript{66} In the present study, L9981 cells showed slightly decreased expression of PHB compared to NL9980 cells. The exact role of PHB in lung cancer metastasis remains under investigation.

PRDX3 functions as an antioxidant and is localized in the mitochondrion. PRDX3 overexpression is associated with the cancer development, progression, and drug resistance. Results suggest that PRDX3 is upregulated in prostate cancer and plays an essential role in regulating oxidation-induced apoptosis in anti-androgen-resistant prostate cancer cells.\textsuperscript{67,68} Moreover, PRDX3 is reported to be involved in drug resistance in ovarian cancer. Wang et al. reported that PRDX3 protein expression is significantly higher in platinum-resistant ovarian cancer patients than in platinum-sensitive patients.\textsuperscript{69} Recently, Duan et al. further demonstrated that downregulation of PRDX3 by siRNA enhanced cisplatin induced ovarian cancer cell apoptosis, providing new evidence of the potential application of PRDX3-siRNA in cancer therapy.\textsuperscript{70} Regarding PRDX3 lung cancer, Kim et al. showed that PRDX3 was markedly overexpressed in human squamous cell carcinoma, suggesting that it may play a protective role against oxidative injury in lung cancer.\textsuperscript{71} Our miRNA and protein level results confirm that PRDX3 expression is remarkably decreased in high metastatic lung cancer L9981 compared to low metastatic lung cancer NL9980 cell lines, indicating that PRDX3 might also be involved in the lung cancer metastatic process.

In summary, for the first time, we have identified mitochondrial differential expression profiling between lung

---

**Table 3** Functional enrichment category analyses of mitochondrial differential proteins

| GO ID | GO term                                      | P       | Number of genes |
|-------|----------------------------------------------|---------|-----------------|
| GO ID | GO term                                      | P       | Number of genes |
| 6732  | Coenzyme metabolic process                   | 2.75E-03| 6               |
| 6082  | Organic acid metabolic process               | 1.81E-03| 10              |
| 45333 | Cellular respiration                         | 1.35E-07| 8               |
| 7005  | Mitochondrion organization                   | 1.07E-03| 6               |
| 15980 | Energy derivation by oxidation of organic compounds | 3.68E-06| 8               |
| 22900 | Electron transport chain                     | 1.85E-05| 7               |
| 22904 | Respiratory electron transport chain         | 1.62E-05| 6               |
| 19752 | Carboxylic acid metabolic process            | 1.62E-03| 10              |
| 42180 | Cellulose metabolic process                  | 2.25E-04| 11              |
| 42773 | ATP synthesis coupled electron transport     | 3.40E-04| 5               |
| 43648 | Dicarboxylic acid metabolic process          | 3.72E-03| 4               |
| 44237 | Carboxylic acid metabolic process            | 2.92E-05| 31              |
| 51186 | Cofactor metabolic process                   | 9.28E-04| 7               |
| 6091  | Generation of precursor metabolites and energy | 4.03E-07| 11              |
| 44281 | Small molecule metabolic process             | 1.31E-03| 15              |
| 6119  | Oxidative phosphorylation                    | 2.45E-04| 6               |
| 55114 | Oxidation reduction                         | 3.92E-09| 16              |
| 43436 | Oxoacid metabolic process                    | 1.62E-03| 10              |
| 42773 | Mitochondrial ATP synthase coupled electron transport | 3.40E-04| 5               |
| 8152  | Metabolic process                            | 1.31E-05| 34              |
| 6120  | Mitochondrial electron transport, NADH to ubiquinone | 4.09E-03| 4               |
| 51287 | NAD or NADH binding                         | 1.83E-03| 4               |
| 16903 | Oxidoreductase activity, acting on the aldehyde or oxo | 2.10E-02| 3               |
| 16681 | Oxidoreductase activity, acting on diphenols and its analogues | 4.35E-02| 2               |
| 8137  | NADH dehydrogenase (ubiquinone) activity     | 4.98E-02| 3               |
| 8121  | Ubiquinol-cytochrome-c reductase activity    | 4.35E-02| 2               |
| 16491 | Oxidoreductase activity                      | 2.34E-09| 16              |
| 3954  | NADH dehydrogenase activity                  | 4.98E-02| 3               |
| 50136 | NADH dehydrogenase (quinone) activity        | 4.98E-02| 3               |
| 3824  | Catalytic activity                           | 2.55E-06| 32              |
| 16651 | Oxidoreductase activity, acting on NADH or NADPH | 6.29E-04| 5               |
| 50662 | Coenzyme binding                             | 2.65E-02| 5               |

GO, gene ontology.
Figure 5 A protein–protein interaction subnetwork of differentially expressed mitochondrial proteins between NL9980 and L9981 cell lines with low and high metastatic potential. In this subnetwork, the colored circles (nodes) represent proteins, the yellow circles represent the proteins from our results, and the grey full lines (edges) represent protein–protein interactions.
cancer cells with high and low metastatic potential by screening mitochondrial protein expression. Further investigation is necessary to determine the biological function and the relevance of the identified mitochondrial proteins in the metastatic process of lung cancer.

Acknowledgments
This study was partly supported by grants from the National Natural Science Foundation of China (No. 81572288) and the Key Project of International Cooperation of Science and Technology Innovation between Governments, the National Key Research and Development Plan of China (No. 2016YEE0103400).

Disclosure
No authors report any conflict of interest.

References
1 Sun KX, Zheng RS, Zeng HM et al. [The incidence and mortality of lung cancer in China, 2014]. Chin J Oncol 2018, 23; 40 (11): 805–11 (In Chinese.).
2 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017; 67 (1): 7–30.
3 Chen W, Zheng R, Baade PD et al. Cancer statistics in China, 2015. CA Cancer J Clin 2015; 65 (1): 5–29.
4 Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65 (2): 87–108.
5 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5–29.
6 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66 (1): 7–30. https://doi.org/10.3322/caac.21332.
Lung cancer metastasis mitochondrial proteomic

Z. Liu et al.

7 Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomarkers Prev 2016; 25 (1): 16–27.

8 Wang JB, Fan YG, Jiang Y et al. Attributable causes of lung cancer incidence and mortality in China. Thorac Cancer 2011; 2 (4): 156–63.

9 Zheng R, Zeng H, Zuo T et al. Lung cancer incidence and mortality in China, 2011. Thorac Cancer 2016; 7 (1): 94–9.

10 Xu Y, Cao LJ, Lin LY et al. Quantitative proteomic study of human lung squamous carcinoma and normal bronchial epithelial acquired by laser capture microdissection. J Biomed Biotechnol 2012; 2012: 510418.

11 Deng W, Yan M, Yu T et al. Quantitative proteomic analysis of the metastasis-inhibitory mechanism of miR-193a-3p in non small cell lung cancer. Cell Physiol Biochem 2015; 35: 1677–88.

12 Cui YQ, Geng Q, Yu T et al. Establishment of a highly metastatic cell line with new isolated lung adenocarcinoma cell line. Int J Oncol 2015; 47: 927–40.

13 Verschoor ML, Ungard R, Harbottle A, Jakupciak JP, Parr RL, Singh G. Mitochondria and cancer: Past, present, and future. Biomed Res Int 2013; 2013: 612369.

14 Li W, Zhang X, Wang W et al. Quantitative proteomics analysis of mitochondrial proteins in lung adenocarcinomas and normal lung tissue using iTRAQ and tandem mass spectrometry. Am J Transl Res 2017; 9 (9): 3918–34.

15 Bustos G, Cruz P, Iovy A, Cárdenas C. Endoplasmic reticulum-mitochondria calcium communication and the regulation of mitochondrial metabolism in cancer: A novel potential target. Front Oncol 2017; 7: 199.

16 Chen J-S, Chen K-T, Fan C-W et al. Comparison of membrane fraction proteomic profiles of normal and cancerous human colorectal tissues with gel-assisted digestion and iTRAQ labeling mass spectrometry. FEBs J 2010; 7 (14): 3028–38.

17 Liu Y, Lina B, Li W et al. Increased AAA-TOB3 correlates with lymph node metastasis and advanced stage of lung adenocarcinoma. Int J Biol Markers 2017; 32 (3): e325–32.

18 Yan B, Dong L, Neuzil J. Mitochondria: An intriguing target for killing tumour-initiating cells. Mitochondrion 2016; 26: 86–93.

19 Tian L, Deng YT, Dong X et al. Siamese crocodile bile induces apoptosis in NCI-H1299 human non-small cell lung cancer cells via a mitochondria-mediated intrinsic pathway and inhibits tumorigenesis. Mol Med Rep 2017; 4: 1727–37.

20 Che TF, Lin CW, Wu YY et al. Mitochondrial translocation of EGFR regulates mitochondria dynamics and promotes metastasis in NSCLC. Oncotarget 2015; 6 (35): 37349–66.

21 Yu C, Wang Y, Peng J et al. Mitochondrial calcium uniporter as a target of microRNA-340 and promoter of metastasis via enhancing the Warburg effect. Oncotarget 2017; 8 (48): 83831–44.

22 Li W, Zhang W, Deng W et al. Quantitative proteomic analysis of mitochondrial proteins differentially expressed between small cell lung cancer cells and normal human bronchial epithelial cells. Thorac Cancer 2018; 9 (11): 1366–75.

23 Li Y, Zhou Q, Sun Z et al. [Experimental study on molecular mechanism of nm23-H1 gene transfection reversing the malignant phenotype of human high-metastatic large cell lung cancer cell line]. Zhongguo Fei Ai Za Zhi 2006; 9 (4): 307–11 (In Chinese.).

24 Steeg PS, Horak CE, Miller KD. Clinical-translational approaches to the Nm23-H1 metastasis suppressor. Clin Cancer Res 2008; 14 (16): 5006–12.

25 Marino N, Nakayama J, Collins JW, Steeg PS. Insights into the biology and prevention of tumor metastasis provided by the Nm23 metastasis suppressor gene. Cancer Metastasis Rev 2012; 31 (3–4): 593–603.

26 Che G, Chen J, Liu L et al. Transfection of nm23-H1 increased expression of beta-Catenin, E-Cadherin and TIMP-1 and decreased the expression of MMP-2, CD44v6 and VEGF and inhibited the metastatic potential of human non-small cell lung cancer cell line L9981. Neoplasma 2006; 53 (6): 530–7.

27 Marino N, Marshall JC, Collins JW et al. Nm23-H1 binds to gelsolin and inactivates its actin-severing capacity to promote tumor cell motility and metastasis. Cancer Res 2013; 73 (19): 5949–62.

28 Prabhu VV, Siddikuzaman GVM, Guruvayoorappan C. Targeting tumor metastasis by regulating Nm23 gene expression. Asian Pac J Cancer Prev 2012; 13 (8): 3539–48.

29 Ma W, Chen J, Xue X et al. Alteration in gene expression profile and biological behavior in human lung cancer cell line N19980 by nm23-H1 gene silencing. Biochem Biophys Res Commun 2008; 371 (3): 425–30.

30 Zhao R, Gong L, Li L et al. nm23-H1 is a negative regulator of TGF-β1-dependent induction of epithelial- mesenchymal transition. Exp Cell Res 2013; 319 (5): 740–9.

31 Yu F, Lu L, Zhihao W et al. nm23-H1 gene driven by hTERT promoter induce inhibition of invasive phenotype and metastasis of lung cancer xenograft in mice. Thorac Cancer 2013; 4 (1): 41–52.

32 Zhou QH, Yang XQ, Zhu W et al. Double mutant P96S/S120Gof Nm23-H1 abrogates its NDPK activity and motility-suppressive ability. Biochem Biophys Res Commun 2007; 356 (2): 348–53.

33 Nie Q, Zhou QH, Zhu W et al. [nm23-H1 gene inhibits lung cancer cell invasion through down-regulation of PKC signal pathway]. Chin J Oncol 2006; 28 (5): 334–6 (In Chinese.).

34 Che GW, Zhou QH, Zhu W et al. [Molecular mechanism of reversing metastatic phenotype in human high-metastatic large cell lung cancer cell line L9981 by nm23-H1]. Chin J Cancer 2005; 24 (3): 278–84 (In Chinese.).

35 Zhou QH, Deng YL, Zhu W. Transfection of the metastasis suppressive gen nm23-H1 induce differential protein expression in human high-metastatic large cell lung cancer cell line L9981. Mol Cell Proteomics 2004; 3 (Suppl.10): S63.

36 Zhou QH, Zhu W, Deng YL. Preliminary analysis of two dimensional gel electrophoresis for proteomic of human...
large cell lung cancer cell line before and after transfection of nm23-H1 gene. Molecular & Cellular Proteomics 2004; 3 (Suppl.10): S105.

37 Li Y, Zhou Q, Sun Z et al. [Transfection of the tumor metastasis suppressor gene nm23-H1 can targetly suppress the activity of extracellular signal-regulated protein kinase (ERK) in human high-metastasis large cell lung cancer cell line L9981]. Zhongguo Fei Ai Za Zhi 2004; 7 (1): 8–11 (In Chinese.).

38 Fu J, Zhou Q, Zhu W et al. [Effects of transfection of nm23-H1 gene on β-catenin expression in human high-metastatic large cell lung cancer cell line L9981]. Zhongguo Fei Ai Za Zhi 2004; 7 (6): 471–4 (In Chinese.).

39 Gong L, Wu Z, Guo L et al. Metastasis suppressor Nm23-H1 inhibits STAT3 signaling via a negative feedback mechanism. Biochem Biophys Res Commun 2013; 434 (3): 541–6.

40 Tang XJ, Zhou QH, Zhang SF, Liu LX. [Expressions of Nm23, E-cadherin, and beta-catenin in non-small cell lung cancer and their correlations with metastasis and prognosis.]. Ai Zheng 2005; 24 (5): 616–21 (In Chinese.).

41 Zhou Q, Wang Y, Che G et al. [Establishment and their biological characteristics of clonal cell subpopulations (NL9980 and L9981) from a human lung large cell carcinoma cell line L9981]. Zhongguo Fei Ai Za Zhi 2003; 6 (6): 464–8 (In Chinese.).

42 Carew JS, Huang P. Mitochondrial defects in cancer. Mol Cancer 2002; 1 (9): 1–12.

43 Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144 (5): 646–74.

44 Chou HC, Chan HL. Targeting proteomics to investigate metastasis-associated mitochondrial proteins. J Bioenerg Biomembr 2012; 44 (6): 629–34.

45 Zhu W, Deng Y, Zhou Q et al. [Analysis of two-dimension gel electrophoresis of human large cell lung cancer cell lines with different metastasis potentials]. Zhongguo Fei Ai Za Zhi 2005; 8 (1): 1–7 (In Chinese.).

46 Ye Y, Huang A, Huang C et al. Comparative mitochondrial proteomic analysis of hepatocellular carcinoma from patients. Proteomics Clin Appl 2013; 7 (5–6): 403–15.

47 Liu J, Zhan X, Li M et al. Mitochondrial proteomics of nasopharyngeal carcinoma metastasis. BMC Med Genomics 2012; 5: 62.

48 Park WS, Chung KW, Young MS, Kim SK, Lee YJ, Lee EK. Differential protein expression of lymph node metastases of papillary thyroid carcinoma harboring the BRAF mutation. Anticancer Res 2013; 33 (10): 4357–64.

49 Kiuru M, Launonen V. Hereditary leiomyomatosis and renal cell cancer (HLRCC). Curr Mol Med 2004; 4 (8): 869–75.

50 Yang Y, Lane AN, Ricketts CJ et al. Metabolic reprogramming for producing energy and reducing power in fumarate hydratase null cells from hereditary leiomyomatosis renal cell carcinoma. PLoS One 2013; 8 (8): e72179.
fibrosis, and hepatocellular carcinoma in mice. *Hepatology* 2010; 52 (6): 2096–108.

66 Rajalingam K, Wunder C, Brinkmann V et al. Prohibitin is required for Ras-induced Raf-MEK-ERK activation and epithelial cell migration. *Nat Cell Biol* 2005; 7 (8): 837–43.

67 Basu A, Banerjee H, Rojas H et al. Differential expression of peroxiredoxins in prostate cancer: Consistent upregulation of PRDX3 and PRDX4. *Prostate* 2011; 71 (7): 755–65.

68 Whitaker HC, Patel D, Howat WJ et al. Peroxiredoxin-3 is overexpressed in prostate cancer and promotes cancer cell survival by protecting cells from oxidative stress. *Br J Cancer* 2013; 109 (4): 983–93.

69 Wang XY, Wang HJ, Li XQ. Peroxiredoxin III protein expression is associated with platinum resistance in epithelial ovarian cancer. *Tumour Biol* 2013; 34 (4): 2275–81.

70 Duan J, Lang Y, Song C, Xiong J, Wang Y, Yan Y. siRNA targeting of PRDX3 enhances cisplatin-induced apoptosis in ovarian cancer cells through the suppression of the NF-κB signaling pathway. *Mol Med Rep* 2013; 7 (5): 1688–94.

71 Kim YS, Lee HL, Lee KB et al. Nuclear factor E2-related factor 2 dependent overexpression of sulfiredoxin and peroxiredoxin III in human lung cancer. *Korean J Intern Med* 2011; 26 (3): 304–13.